Our data are in close agreement with previous ones that unraveled survivin/BIRC5 mechanistic events is the pivotal and ubiquitous nature of tumor progression and clinical manifestation; consequently, it could emerge as an attractive therapeutic target in cancer treatment [40-43]. The gene discussed is BIRC5; the disease is cancer.